Grifols starts Tavlesse roll-out in France, Italy and Spain

29 September 2021

Spanish plasma-derived medicines company Grifols (GRF: MC) has announced that Tavlesse (fostamatinib), used to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments, is now available in France, Italy and Spain and reimbursable from their respective health systems.

Fostamatinib is the first and only SYK (spleen tyrosine kinase) inhibitor indicated in adult patients with ITP who have had an insufficient response to a previous treatment. It is the only targeted agent that reduces the immune system’s destruction of platelets, which are critical for blood clotting and healing.

Medical associations such as the Spanish Society of Hematology and Hemotherapy (SEHH in Spanish) and the Spanish Group for Immune Thrombocytopenia (GEPTI) include fostamatinib in their recommendations to treat ITP.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK